The Effects of Vyvanse(TM) on Brain Hemodynamics and Reading (VBHR)
|ClinicalTrials.gov Identifier: NCT00733356|
Recruitment Status : Completed
First Posted : August 13, 2008
Results First Posted : February 14, 2018
Last Update Posted : February 14, 2018
|Condition or disease||Intervention/treatment||Phase|
|Attention Deficit/Hyperactivity Disorder||Drug: Vyvanse||Phase 4|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||42 participants|
|Intervention Model:||Single Group Assignment|
|Primary Purpose:||Basic Science|
|Official Title:||The Effects of Vyvanse(TM) on Brain Hemodynamics and Reading|
|Study Start Date :||July 2008|
|Primary Completion Date :||September 2009|
|Study Completion Date :||September 2009|
Experimental: Vyvanse Treatment
All subjects were tested at baseline before medication and then titrated to best dose and retested on Vyvanse Medication.
Subjects will participate in an open-label dose optimization period and successful titration to an optimal dose of Vyvanse™, subjects will take their optimized dose of Vyvanse™ (30, 50 or 70 mg/day) during the week leading up to their final visit. During the study subjects will take their prescribed dose once a day in the morning with breakfast.
Other Name: lisdexamfetamine dimesylate
- Gray Oral Reading Rest, Fourth Edition (GORT-4) [ Time Frame: baseline and final day (lab school Assessments) ]
The GORT-4 evaluates oral reading rate, accuracy and comprehension. Both Forms A and B were used.Half of the subjects randomly were tested on From A at baseline and the other half were tested with Form B.
The GORT-4 is a standardized measure/test. Scores provided are standard scores, which range from 1 to 20, with a Mean of 10 and Standard Deviation of 3. A higher score means better reading performance. There was no total score used or calculated in this study.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00733356
|United States, California|
|University of California, Irvine Child Development Center|
|Irvine, California, United States, 92697|
|Principal Investigator:||Kimberley Lakes, PhD||UC Irvine|